CAJ | 학술논문

背景:骨髓间充质干细胞移植可减轻肝硬化程度,改善肝功能.目的:观察不同途径移植骨髓间充质干细胞对四氯化碳诱导大鼠肝硬化的作用.方法:将60只SD大鼠随机分为正常组、对照组、门静脉移植组、肝动脉移植组、尾静脉移植组,后4组采用四氯化碳联合乙醇制作肝硬化模型,对照组不进行移植,其余3组分别经门静脉、肝动脉、尾静脉移植大鼠骨髓间充质干细胞1×106.结果与结论:移植4周后,与对照组比较,移植3组大鼠肝功能均得到明显改善,血清白蛋白、胆碱酯酶显著升高(P<0.05),转氨酶、胆红素、凝血时间、Ⅳ型胶原显著降低(P<0.05),肝纤维化程度显著减轻(P<0.05).门静脉移植组及肝动脉移植组优于尾静脉移植组,前两者之间差异无显著性意义(P>0.05).说明经门静脉、肝动脉、尾静脉移植骨髓间充质干细胞均可减轻肝纤维化程度,改善肝功能,但肝动脉及门静脉移植途径优于外周血静脉途径.
배경:골수간충질간세포이식가감경간경화정도,개선간공능.목적:관찰불동도경이식골수간충질간세포대사록화탄유도대서간경화적작용.방법:장60지SD대서수궤분위정상조、대조조、문정맥이식조、간동맥이식조、미정맥이식조,후4조채용사록화탄연합을순제작간경화모형,대조조불진행이식,기여3조분별경문정맥、간동맥、미정맥이식대서골수간충질간세포1×106.결과여결론:이식4주후,여대조조비교,이식3조대서간공능균득도명현개선,혈청백단백、담감지매현저승고(P<0.05),전안매、담홍소、응혈시간、Ⅳ형효원현저강저(P<0.05),간섬유화정도현저감경(P<0.05).문정맥이식조급간동맥이식조우우미정맥이식조,전량자지간차이무현저성의의(P>0.05).설명경문정맥、간동맥、미정맥이식골수간충질간세포균가감경간섬유화정도,개선간공능,단간동맥급문정맥이식도경우우외주혈정맥도경.
BACKGROUND:Transplantation of bone marrow mesenchymal stem cel s can al eviate cirrhosis and improve liver function. OBJECTIVE:To investigate the differences among the curative effects of three transplantation approaches of mesenchymal stem cel s (MSCs) in a rat model of cirrhosis. METHODS:60 SD rats were randomly divided into five groups:normal, control, portal vein transplantation, hepatic artery transplantation and tail vein transplantation groups. The rat model of CC14 and alcohol-induced cirrhosis was prepared in the latter four groups. Rats in the portal vein transplantation, hepatic artery transplantation and tail vein transplantation groups received 1×106 al ogenic rat bone marrow mesenchymal stem cel s via the portal vein, hepatic artery and tail vein, respectively. The control group rats received no transplantation. RESULTS AND CONCLUSION:Compared with the control group, the liver function of cirrhosis rats in the three transplantation groups was improved significantly, the levels of serum albumin and cholinesterase were significantly increased (P<0.05), the levels of transaminases, bilirubin, prothrombin time, type IV col agen were significantly decreased, and the degree of cirrhosis was significantly al eviated (P<0.05) at 4 weeks after transplantation in the three transplantation groups. The outcomes were significantly superior in the portal vein transplantation and hepatic artery transplantation groups than in the tail vein transplantation group (P>0.05). These findings suggest that portal vein transplantation and hepatic artery transplantation can better al eviate the degree of cirrhosis and improve hepatic function than tail vein transplantation, and there is no significant difference between the former two groups.